NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Novartis' remibrutinib showed a 30% reduction in disability progression in a Phase III trial for multiple sclerosis (MS). The drug also increased the proportion of patients with no evidence of disease activity. Novartis estimates a $4B opportunity for remibrutinib in relapsing MS. The company reported no major safety differences compared to teriflunomide. Novartis is conducting additional studies, with results expected in 2028 and 2031.

Novartis reported that Kisqali (ribociclib) plus endocrine therapy reduced death risk by 19.1% in a six-year study of early breast cancer. The trial showed a 2.1 percentage point overall-survival difference at year six. No new safety concerns were identified. The data will be presented at the 2026 ESMO Congress.

Novartis' remibrutinib, an oral BTK inhibitor, reduced annualized relapse rate by 35.2% and 31.2% in two phase 3 trials for relapsing multiple sclerosis (RMS) compared to teriflunomide. The trials also showed improvements in disability progression and MRI outcomes. Novartis plans to seek global regulatory approval for remibrutinib in RMS.

Novartis' remibrutinib reduced MS relapses by 35.2% and 31.2% vs. teriflunomide, below analyst expectations of 45-60%. Roche's competing drug fenebrutinib showed a 55% reduction. Novartis highlights remibrutinib's potential, with analysts estimating peak sales over $4B if approved. Safety concerns remain for both drugs.

Novartis reported relapse data for its multiple sclerosis drug remibrutinib that fell short of expectations. The company's shares have seen a 5-day change of 128.00 CHF, a 1st Jan change of -0.68%, and a year-to-date increase of 16.79%.